BioCardia, Inc. (BCDA)

0.3766 +0.0108 (+2.95%) At close: 04:00PM EDT

BioCardia, Inc.

320 Soquel Way
Sunnyvale, CA 94085
United States
650 226 0120
https://www.biocardia.com

Sector(s): Healthcare
Industry: Biotechnology
Full Time Employees: 16

Key Executives

Name	Title	Pay	Exercised	Year Born
Dr. Peter A. Altman Ph.D.	CEO, President & Director	515.51k	N/A	1967
Mr. David McClung	Chief Financial Officer	370.86k	N/A	1963
Mr. Edward M. Gillis	Senior Vice President of Devices	263.1k	N/A	1962

Amounts are as of December 31, 2023 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.

Description

BioCardia, Inc., a clinical-stage regenerative medicine company, engages in development of cellular and cell-derived therapeutics for cardiovascular and pulmonary diseases. Its lead therapeutic candidate is the CardiAMP, an autologous mononuclear cell therapy system for the treatment of heart failure and chronic myocardial ischemia; and allogeneic cell therapy for cardiac and pulmonary disease. The company is also developing allogeneic cells therapeutic platform, an investigational culture expanded bone marrow derived mesenchymal cell therapy, which is in Phase I/II trial for the treatment of ischemic heart failure. In addition, it offers the Helix biotherapeutic delivery system that delivers therapeutics into the heart muscle with a penetrating helical needle from within the heart; and Morph deflectable guides and sheaths. The company is based in Sunnyvale, California.

Corporate Governance

BioCardia, Inc.’s ISS Governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder Rights: N/A; Compensation: N/A.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.